JP7595336B2 - Antibacterial Water Composition - Google Patents
Antibacterial Water Composition Download PDFInfo
- Publication number
- JP7595336B2 JP7595336B2 JP2020148557A JP2020148557A JP7595336B2 JP 7595336 B2 JP7595336 B2 JP 7595336B2 JP 2020148557 A JP2020148557 A JP 2020148557A JP 2020148557 A JP2020148557 A JP 2020148557A JP 7595336 B2 JP7595336 B2 JP 7595336B2
- Authority
- JP
- Japan
- Prior art keywords
- antibacterial
- virus
- composition
- test
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 63
- 239000000203 mixture Substances 0.000 title claims description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 42
- 241000700605 Viruses Species 0.000 claims description 40
- 229940024606 amino acid Drugs 0.000 claims description 14
- 235000001014 amino acid Nutrition 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 230000002779 inactivation Effects 0.000 claims description 13
- 241000714201 Feline calicivirus Species 0.000 claims description 10
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 241000712461 unidentified influenza virus Species 0.000 claims description 9
- 230000000415 inactivating effect Effects 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 7
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
- 235000014852 L-arginine Nutrition 0.000 claims description 5
- 229930064664 L-arginine Natural products 0.000 claims description 5
- 229960002885 histidine Drugs 0.000 claims description 5
- 239000003002 pH adjusting agent Substances 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 4
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 6
- 239000000645 desinfectant Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003899 bactericide agent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000001139 pH measurement Methods 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000005727 virus proliferation Effects 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- -1 Fatty acid ester Chemical class 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241001135549 Porcine epidemic diarrhea virus Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
本発明は、抗菌水用組成物に関し、特に、安全性を有する抗菌水用組成物に関する。 The present invention relates to an antibacterial water composition, and in particular to a safe antibacterial water composition.
抗菌水には一般的に、中身や容器が微生物により腐敗などの変性を起こさないように、微生物の繁殖や成育を抑制する防腐・殺菌成分が配合されている。多くの防腐・殺菌成分は、配合可能成分リスト（ポジティブリスト）に記載されているので、配合規制がある。 Antibacterial water generally contains preservative and bactericidal ingredients that inhibit the proliferation and growth of microorganisms to prevent the contents and container from deteriorating or becoming rotten by microorganisms. Many preservative and bactericidal ingredients are listed on a list of ingredients that can be added (positive list), so there are restrictions on their addition.
例えば、殺菌剤を含む拭き取り用の抗菌水であって、敏感肌用、ニキビ予防用、及びニキビ改善用からなる群より選ばれた用途に用いられ、下記成分（Ａ）、下記成分（Ｂ）、下記成分（Ｃ）、下記成分（Ｄ）、及び下記成分（Ｅ）を含むことを特徴とする抗菌水が知られている（特許文献１）。
成分（Ａ）：抗炎症剤
成分（Ｂ）：殺菌剤
成分（Ｃ）：脂肪酸エステル非イオン性界面活性剤
成分（Ｄ）：保湿剤
成分（Ｅ）：水
For example, there is known an antibacterial water for wiping containing a germicide, which is used for an application selected from the group consisting of for sensitive skin, for preventing acne, and for improving acne, and which is characterized by containing the following component (A), component (B), component (C), component (D), and component (E) (Patent Document 1).
Component (A): Anti-inflammatory agent Component (B): Bactericide Component (C): Fatty acid ester nonionic surfactant Component (D): Moisturizer Component (E): Water
このように、上述の特許文献１を含め従来技術においては、中身や容器が微生物により腐敗などの変性を起こさないように、殺菌剤を含むものが多いのが現状である。一方で、未だにこれらの抗菌成分等は有害であるという認識を持つ消費者が多いことから、防腐・殺菌剤を配合しないことが望まれる。したがって、使用する前に、内容物や容器が微生物により腐敗などの変性を起こさないように、防腐・殺菌成分以外の手段によって、微生物の繁殖や成育を抑制することができれば望ましい。 As described above, in the prior art, including Patent Document 1, many products currently contain disinfectants to prevent the contents or container from deteriorating, such as spoiling, due to microorganisms. However, since many consumers still believe that these antibacterial ingredients are harmful, it is preferable not to include preservatives or disinfectants. Therefore, it would be desirable to be able to inhibit the proliferation and growth of microorganisms by means other than preservative or disinfectant ingredients, so that the contents or container do not degrade, such as spoiling, due to microorganisms, before use.
そこで、本発明は、抗菌力を有し、安全性を有する抗菌水組成物を提供することにある。 Therefore, the present invention aims to provide an antibacterial aqueous composition that has antibacterial activity and is safe.
上記目的を達成するために、本発明者らは、防腐、殺菌成分を配合することなく、抗菌性を有する組成物について鋭意検討した結果、本発明を見出すに至った。 To achieve the above objective, the inventors conducted extensive research into compositions that have antibacterial properties without incorporating preservative or bactericidal ingredients, and as a result, came up with the present invention.
すなわち、本発明のウイルス不活性化用抗菌水用組成物を用いたウイルスの不活性化方法（但し、人間を治療する方法を除く。）は、Ｌ－システイン、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン、又はこれらの塩の少なくとも1種のアミノ酸と、還元性イオン水とを含有するウイルス不活性化用抗菌水用組成物であって、前記ウイルス不活性化用抗菌水用組成物のｐHは１０．９４４～１１．６３９であり、前記アミノ酸の含有量は、前記ウイルス不活性化用抗菌水用組成物の全量に対して、０．００１質量％～０．０１質量％の範囲であり、前記還元性イオン水の含有量は、前記ウイルス不活性化用抗菌水用組成物の全量に対して、１０～２０質量％の範囲であることを特徴とするウイルス不活性化用抗菌水用組成物を用いて、ウイルスを不活性化することを特徴とする。
That is, the method for inactivating viruses using the virus inactivating antibacterial aqueous composition of the present invention (excluding methods for treating humans) is characterized in that viruses are inactivated using a virus inactivating antibacterial aqueous composition containing at least one amino acid selected from L-cysteine, L-arginine, L-lysine, L-histidine, or a salt thereof, and reducing ion water, wherein the pH of the virus inactivating antibacterial aqueous composition is 10.944 to 11.639, the content of the amino acid is in the range of 0.001% by mass to 0.01% by mass , relative to the total amount of the virus inactivating antibacterial aqueous composition, and the content of the reducing ion water is in the range of 10 to 20% by mass, relative to the total amount of the virus inactivating antibacterial aqueous composition.
また、本発明のウイルス不活性化用抗菌水用組成物を用いたウイルスの不活性化方法の好ましい実施態様において、前記ウイルスは、インフルエンザウイルス、ネコカリシウイルス、又はPEDウイルスであることを特徴とする。
In a preferred embodiment of the method for inactivating a virus using the antibacterial water composition for virus inactivation of the present invention, the virus is an influenza virus, a feline calicivirus, or a PED virus .
また、本発明の抗菌水用組成物の好ましい実施態様において、ｐH調整剤を含有しないことを特徴とする。 In a preferred embodiment of the antibacterial aqueous composition of the present invention, the composition does not contain a pH adjuster.
本発明の抗菌水用組成物によれば、いわゆる防腐剤や殺菌剤を配合せず、抗菌性を有する抗菌水用組成物の提供が可能であるという有利な効果を奏する。 The antibacterial water composition of the present invention has the advantageous effect of being able to provide an antibacterial water composition that has antibacterial properties without the inclusion of so-called preservatives or bactericides.
本発明の抗菌水用組成物は、Ｌ－システイン、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン、又はこれらの塩類の少なくとも1種のアミノ酸を含有する抗菌水用組成物であって、前記抗菌水用組成物のｐHは１０．９以上、より好ましくは、１１．５以上であることを特徴とする。これは、抗菌成分等の添加を望まない消費者に対して、いわゆる防腐・殺菌剤を配合せずに、抗菌作用を有する組成物を提供しようとするものである。なお、Ｌ－システイン及びその塩類は毛髪の保湿および柔軟性を保たせることが可能であり、Ｌ－アルギニン、Ｌ－リシン、Ｌ－ヒスチジン等は毛髪の損傷により毛髪から流出するため、添加することにより、アミノ酸成分を補充することも可能となる。 The antibacterial water composition of the present invention is an antibacterial water composition containing at least one amino acid, L-cysteine, L-arginine, L-lysine, L-histidine, or salts thereof, and is characterized in that the pH of the antibacterial water composition is 10.9 or higher, more preferably 11.5 or higher. This is to provide a composition with antibacterial activity without blending so-called preservatives and disinfectants to consumers who do not wish to add antibacterial ingredients. Furthermore, L-cysteine and its salts can keep hair moisturized and flexible, and since L-arginine, L-lysine, L-histidine, etc. are lost from hair due to damage, adding them can also replenish amino acid components.
このように、本発明においては、アルカリ度が極めて低いため塗布されたときに肌の中和能で瞬時に弱酸性になり、肌に刺激のない抗菌水とすることができる。したがって、肌に塗布される前は、ｐＨ１０．９以上～ｐＨ１１．５付近なので防腐剤を配合しなくても抗菌性のある抗菌水であり、肌に塗布されると瞬時に弱酸性（肌表面でｐＨ６．０付近）になることを特徴の一つとすることができる。 In this way, in the present invention, since the alkalinity is extremely low, when applied, the skin's neutralizing ability instantly makes it weakly acidic, making it an antibacterial water that is not irritating to the skin. Therefore, one of the characteristics of this invention is that before it is applied to the skin, the pH is between 10.9 and around 11.5, so it is an antibacterial water that has antibacterial properties even without the addition of preservatives, and when applied to the skin, it instantly becomes weakly acidic (around pH 6.0 on the skin surface).
また、本発明の抗菌水用組成物の好ましい実施態様において、前記アミノ酸の含有量は、抗菌水用組成物の全量に対して、０．００００１質量％～１．０質量％の範囲、より好ましくは、０．０００１質量％～０．０１質量％の範囲であることを特徴とする。かかる範囲としたのは、この程度の量であれば、抗菌性を有する組成物として効果を発揮し得るからである。
In a preferred embodiment of the antibacterial aqueous composition of the present invention, the content of the amino acid is in the range of 0.00001% by mass to 1.0% by mass , more preferably in the range of 0.0001% by mass to 0.01% by mass , based on the total amount of the antibacterial aqueous composition. The reason for setting the range as above is that the composition can be effective as an antibacterial composition at this amount.
本発明において、ｐH値の調整は、配合するアミノ酸の種類、配合量等により適宜調整可能である。一般に、炭酸ナトリウムの他、炭酸ソーダ、炭酸水素ナトリウム等を含めｐH調整剤を用いて調整することができるが、このようなｐH調整剤の使用は、組成物のアルカリ度が高くなりｐＨを維持する力は強くなり、肌に塗布した場合は瞬時に弱酸性には戻りづらくなる傾向がある。 In the present invention, the pH value can be adjusted as appropriate by adjusting the type and amount of the amino acid to be blended. In general, the pH value can be adjusted using a pH adjuster including sodium carbonate, sodium carbonate, sodium bicarbonate, etc., but the use of such a pH adjuster increases the alkalinity of the composition and strengthens its ability to maintain the pH, and when applied to the skin, it tends to be difficult to instantly return to a weakly acidic state.
したがって、かかる観点から、本発明の好ましい実施態様において、ｐH調整剤を含有しないことを特徴とする。 Therefore, from this perspective, a preferred embodiment of the present invention is characterized in that it does not contain a pH adjuster.
また、本発明において、前記抗菌水用組成物のｐHは１０．９以上であるとしたのは、このようなｐH値であれば、いわゆる防腐・殺菌成分を添加しなくても、多くの好アルカリ性微生物を排除することが可能だからである。 In addition, in the present invention, the pH of the antibacterial aqueous composition is set to 10.9 or higher because such a pH value makes it possible to eliminate many alkaliphilic microorganisms without adding so-called antiseptic or bactericidal components.
また、本発明の抗菌水用組成物の好ましい実施態様において、さらに、還元性イオン水を含有することを特徴とする。上述のように、ｐH値の調整は、配合するアミノ酸の種類、配合量等により適宜調整可能であるが、配合するアミノ酸や配合量によっては、所望のpH値を達成できない虞もある。この場合には、還元性イオン水を使用することができる。還元イオン水は、電気分解され、アルカリ性を示す水とすることができる。例えば、還元イオン水としては、株式会社エー・アイ・システムプロダクトが製造販売するＳ－１００等を挙げることができ、Ｓ-１００は、、電気分解された高機能還元性イオン水で、化粧品表示名称は「水」、ｐＨ１２±０．５のアルカリ性水である。 In a preferred embodiment of the antibacterial water composition of the present invention, the composition further contains reduced ionized water. As described above, the pH value can be adjusted as appropriate by the type and amount of the amino acid to be blended, but depending on the amino acid and the amount to be blended, there is a risk that the desired pH value cannot be achieved. In this case, reduced ionized water can be used. The reduced ionized water can be water that is electrolyzed and exhibits alkaline properties. For example, reduced ionized water can be S-100 manufactured and sold by AI System Products Co., Ltd. S-100 is electrolyzed high-performance reduced ionized water, labeled as "water" in cosmetics, and is alkaline water with a pH of 12±0.5.
また、本発明の抗菌水用組成物の好ましい実施態様において、抗菌水用組成物の全量に対して、前記還元性イオン水の含有量は、１０質量％～９０質量％の範囲、より好ましくは、１０質量％～２０質量％の範囲であることを特徴とする。 In a preferred embodiment of the antibacterial water composition of the present invention, the content of the reducing ion water is in the range of 10% by mass to 90% by mass, more preferably in the range of 10% by mass to 20% by mass, relative to the total amount of the antibacterial water composition.
以下では本発明の抗菌水用組成物の一例について実施例を用いて説明するが、本発明は、下記の実施例に限定して解釈されるものではない。 Below, an example of the antibacterial aqueous composition of the present invention will be described using an example, but the present invention should not be interpreted as being limited to the following example.
実施例１
まず、アルカリ性を呈し、防腐・殺菌成分を配合しない頭髪・肌の抗菌水用組成物の一例を試みた。アミノ酸の一例として、アルギニンを用いた。具体的に、精製水99.0質量％にＬ(+)―アルギニン（和光純薬工業（株）製）１．０％質量を配合して、アルカリ性水溶液を作成しｐＨを測定した。また、参照のため、精製水８０．０質量％に電解還元性イオン水Ｓ－１００（（株）エー・アイ・システムプロダクト製）を２０質量％配合し、アルカリ性水溶液を作成しｐＨを測定した。
Example 1
First, an example of an antibacterial aqueous composition for hair and skin that exhibits alkalinity and does not contain any preservative or bactericidal ingredients was tried. Arginine was used as an example of an amino acid. Specifically, 1.0% mass of L(+)-arginine (manufactured by Wako Pure Chemical Industries, Ltd.) was mixed with 99.0% mass of purified water to prepare an alkaline aqueous solution, and the pH was measured. For reference, 20% mass of electrolytically reduced ion water S-100 (manufactured by AI System Products Co., Ltd.) was mixed with 80.0% mass of purified water to prepare an alkaline aqueous solution, and the pH was measured.
なお、ｐＨ測定には以下の機種及び電極を用いた。
ｐＨメーターの機種：pH METER F-71（（株）堀場製作所）
ｐＨメーターの電極：＃9615-10D（（株）堀場製作所）
The following models and electrodes were used for the pH measurements.
pH meter model: pH METER F-71 (HORIBA, LTD.)
pH meter electrode: #9615-10D (HORIBA, LTD.)
実施例２
次に、精製水７９．０質量％にＳ－１００を２０．０質量％、Ｌ－アルギニン１．０質量％を配合して、アルカリ性水溶液を作成し、実施例１と同様にｐＨを測定した。
Example 2
Next, 79.0% by mass of purified water was mixed with 20.0% by mass of S-100 and 1.0% by mass of L-arginine to prepare an alkaline aqueous solution, and the pH was measured in the same manner as in Example 1.
表１に、実施例１～２、参照例のｐＨ測定値を示す。 Table 1 shows the pH measurement values for Examples 1 and 2 and the Reference Example.
表１の結果から参照例のｐＨ測定値が一番高いことが判明した。 The results in Table 1 show that the pH measurement value of the reference example was the highest.
実施例３～６
表１の結果をもとに、実施例１と同様の手順に従って、種々の調整例を作成した。表２は、本発明の一実施態様における抗菌水用組成物の成分例及び調整例を示す。
Examples 3 to 6
Based on the results in Table 1, various preparation examples were prepared according to the same procedure as in Example 1. Table 2 shows example components and preparation examples of the antibacterial aqueous composition in one embodiment of the present invention.
実施例７
次に、アミノ酸として、L-ヒスチジンを用いて、かつ、種々の量の還元イオン水を用いて、上述の実施例の手順に従って、本発明の抗菌水用組成物を作成した。その結果を、表４に示す。
Example 7
Next, antibacterial aqueous compositions of the present invention were prepared according to the procedure of the above-mentioned examples using L-histidine as the amino acid and various amounts of reduced ion water. The results are shown in Table 4.
これらの結果、ｐＨ１０．９以上の組成物を作成することができ、いわゆる防腐剤、殺菌剤を含むことなく、抗菌性を有する組成物を作成するできることが判明した。また、仮に、３種類の塩基性アミノ酸を同量配合する場合には、０．００１％以下が好ましいことが判明した。 As a result of these studies, it was found that it is possible to create a composition with a pH of 10.9 or higher, and that it is possible to create a composition with antibacterial properties without the use of so-called preservatives or disinfectants. In addition, it was found that if three types of basic amino acids are mixed in equal amounts, a concentration of 0.001% or less is preferable.
また、本発明においては、炭酸ナトリウムの他、炭酸ソーダ、炭酸水素ナトリウム等のｐH調整剤を使用していないので、アルカリ度が極めて低い組成物を提供することができるので肌に塗布されたときに肌の中和能で瞬時に弱酸性になり肌を刺激しないという有利な効果を奏する。さらに、本発明の組成物を頭髪に塗布した場合にはアルカリ性の時に毛髪への浸透性を高め、塩基性アミノ酸を補うことが可能であることが判明した。 In addition, the present invention does not use any pH adjusters such as sodium carbonate, sodium carbonate, or sodium bicarbonate, other than sodium carbonate, and is therefore able to provide a composition with extremely low alkalinity, which has the advantageous effect of instantly becoming weakly acidic when applied to the skin due to the skin's neutralizing ability, and not irritating to the skin. Furthermore, it has been found that when the composition of the present invention is applied to hair, it is possible to increase the penetration into the hair when it is alkaline, and to supplement basic amino acids.
実施例８
次に、実際に、本発明の抗菌水用組成物について、各種ウイルスを用いて、当該ウイルスの不活性化効果を調べた。具体的に、本発明の抗菌水用組成物と、インフルエンザウイルス、ネコカリシウイルス、PEDウイルスとを反応させた時のウイルス不活化効果を確認した。対照資材として滅菌リン酸緩衝液を使用した。ウイルス不活化試験に使用した本発明の抗菌水用組成物の成分を、表５に示す。
Example 8
Next, the antibacterial aqueous composition of the present invention was actually used to examine the inactivation effect of various viruses. Specifically, the virus inactivation effect was confirmed when the antibacterial aqueous composition of the present invention was reacted with influenza virus, feline calicivirus, and PED virus. Sterile phosphate buffer was used as a control material. The components of the antibacterial aqueous composition of the present invention used in the virus inactivation test are shown in Table 5.
供試微生物については、以下の通りである。
・インフルエンザウイルス：swine influenza virus H1N1 IOWA株、培養細胞： MDCK細胞 （イヌ腎臓由来株化細胞）
・ネコカリシウイルス：feline calicivirus F9 株、培養細胞： CRFK細胞 （ネコ腎臓由来株化細胞）※ノロウイルス代替
・PEDウイルス： Porcine epidemic diarrhea virus P-5V 株、培養細胞： vero細胞（アフリカミドリザルの腎臓上皮由来株化細胞）※豚感染性のコロナウイルス（新型コロナウイルス代替として）
The microorganisms tested are as follows:
Influenza virus: swine influenza virus H1N1 IOWA strain, cultured cells: MDCK cells (canine kidney-derived cell line)
Feline calicivirus: feline calicivirus F9 strain, cultured cells: CRFK cells (cat kidney derived cell line) *Norovirus substitute
・PED virus: Porcine epidemic diarrhea virus P-5V strain, cultured cells: Vero cells (cell line derived from the kidney epithelium of African green monkeys) *Pig-infectious coronavirus (as an alternative to the new coronavirus)
試験区等の設定については、試験区においては、以下の通りである。
処置：試験資材（本発明の抗菌水用組成物）1mLにウイルス液0.1mL添加
感作時間：試験開始後30分
Regarding the establishment of test areas, etc., the test areas are as follows.
Treatment: 0.1 mL of virus solution was added to 1 mL of test material (antibacterial aqueous composition of the present invention). Sensitization time: 30 minutes after the start of the test.
対照区においては、以下の通りである。
処置：リン酸緩衝液1mLにウイルス液0.1mL添加
感作時間：試験開始後 0分、 30 分
In the control area, the results are as follows:
Treatment: 0.1 mL of virus solution added to 1 mL of phosphate buffer solution. Sensitization time: 0 minutes and 30 minutes after the start of the test.
試験方法については、「ウイルス実験学 総論 改訂二版 丸善株式会社 ウイルス中和試験法」を参考として実施した 。 The test method was based on "Virus Experimental Science: General Theory, Revised 2nd Edition, Maruzen Co., Ltd., Virus Neutralization Test Method."
＜試験 手順＞
１）予備試験：
試験に先立って、試験資材が培養細胞に与える影響（細胞毒性）を調査した。試験資材をリン酸緩衝液で10倍段階希釈した後、培養細胞に接種し、培養後の細胞の正常な状態を示す最高濃度を確認し、試験に使用するウイルス濃度を決定した。その結果、細胞毒性について、MDCK細胞、CRFK細胞、vero細胞のいずれにおいても確認されなかった。この為、各ウイルス添加濃度は105 TCID50 /mL以上、検出限界は<101.5TCID50/mLとした。
<Test procedure>
1) Preliminary test:
Prior to the test, the effect of the test materials on cultured cells (cytotoxicity) was investigated. The test materials were serially diluted 10-fold with phosphate buffer, then inoculated into the cultured cells to confirm the highest concentration that showed the normal state of the cells after culture, and the virus concentration to be used in the test was determined. As a result, no cytotoxicity was confirmed in any of the MDCK cells, CRFK cells, or vero cells. For this reason, the virus addition concentration was set at 10 5 TCID 50 /mL or more, and the detection limit was set at <10 1.5 TCID50/mL.
２）本試験・試験液混合：
試験区分に従い、試験資材及びリン酸緩衝液の各1mLをそれぞ分取し、予備試験で決定した濃度にウイルス液を添加した。ウイルス液添加後、混合液として室温（25℃）にて所定の時間静置した。
2) Main test/test solution mixture:
According to the test category, 1 mL of each test material and phosphate buffer solution was taken, and the virus solution was added to the concentration determined in the preliminary test. After adding the virus solution, the mixture was left to stand at room temperature (25°C) for the specified time.
３）本試験・細胞接種及び菌数測定：
試験区分ごとに感作が終了した混合液をそれぞれ10倍段階希釈し、96wellプレートに培養した細胞に100μLずつ接種した。判定は、37℃、炭酸ガス培養（5％）で5日間培養した後、インフルエンザウイルスの場合は、各ウェル内の培養上清を回収し、赤血球凝集反応によりウイルスの増殖の有無を確認し、その濃度を算出した。また、ネコカリシウイルス及び PEDウイルスの場合は、培養細胞を顕微鏡観察し、培養細胞に現れるCPE（細胞変性）をもってウイルス増殖の有無を確認し、その濃度を算出した。
3) Main test: Cell inoculation and bacterial count:
After sensitization for each test category, the mixture was diluted 10-fold and 100μL was inoculated into the cells cultured in a 96-well plate. After 5 days of incubation at 37℃ in carbon dioxide gas (5%), in the case of influenza virus, the culture supernatant in each well was collected and the presence or absence of virus proliferation was confirmed by hemagglutination reaction, and the concentration was calculated. In the case of feline calicivirus and PED virus, the cultured cells were observed under a microscope, and the presence or absence of virus proliferation was confirmed by CPE (cytopathic change) that appeared in the cultured cells, and the concentration was calculated.
＜結果＞
１）インフルエンザウイルス
インフルエンザウイルスに対する試験結果を図1にした。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった（108.1TCID50/mL（130000000））。試験区では開始後30分で103.9TCID50/mL（8000）（99.99％減少）となった。
<Results>
1) Influenza virus The test results for influenza virus are shown in Figure 1. In the control group, no change in viral load was observed from the start of the test up to 30 minutes (10 8.1 TCID 50 /mL (130 million)). In the test group, the viral load was 10 3.9 TCID 50 /mL (8000) (a 99.99% reduction) 30 minutes after the start.
２）PEDウイルス
PEDウイルスに対する試験結果を図2に示した。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった （108.1TCID50/mL（130000000））。試験区では開始後30分で103.9TCID50/mL（8000）（99.99％減少）となった。
2) PED virus
The test results for the PED virus are shown in Figure 2. In the control group, no change in viral load was observed from the start of the test until 30 minutes later (10 8.1 TCID 50 /mL (130 million)). In the test group, the viral load was 10 3.9 TCID 50 /mL (8000) (a 99.99% reduction) 30 minutes after the start of the test.
３）ネコカリシウイルス
ネコカリシウイルスに対する試験結果を図3に示した。対照区では試験開始後から、30分までの間にウイルス量変化は見られなかった（106.7TCID50/mL（5000000））。試験区では開始後30分で101.9TCID50/mL（99.99％減少）となった。
3) Feline calicivirus The test results for feline calicivirus are shown in Figure 3. In the control group, no change in the viral load was observed from the start of the test up to 30 minutes (10 6.7 TCID 50 /mL (5,000,000)). In the test group, the viral load was 10 1.9 TCID 50 /mL (a 99.99% reduction) 30 minutes after the start.
今回、試験資材のインフルエンザウイルス、ネコカリシウイルス及びPEDウイルスに対する不活化効果試験を実施した。その結果、試験資材（本発明の抗菌水用組成物）はインフルエンザウイルス、ネコカリシウイルス、及びPEDウイルスに対して30分以上の反応で99.99％以上のウイルス不活化効果があることが判明した。 This time, we conducted tests on the inactivation effect of the test material against influenza virus, feline calicivirus, and PED virus. As a result, it was found that the test material (the antibacterial water composition of the present invention) has a virus inactivation effect of 99.99% or more against influenza virus, feline calicivirus, and PED virus in a reaction of 30 minutes or more.
本発明によると、防腐剤、殺菌剤を配合することなく、抗菌性を有することから、広い分野において産業上利用価値が高い。 The present invention has antibacterial properties without the use of preservatives or bactericides, making it highly useful in a wide range of industrial fields.
Claims (3)
The method according to claim 1 or 2, characterized in that the antibacterial aqueous composition for virus inactivation does not contain a pH adjuster.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020148557A JP7595336B2 (en) | 2020-09-03 | 2020-09-03 | Antibacterial Water Composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020148557A JP7595336B2 (en) | 2020-09-03 | 2020-09-03 | Antibacterial Water Composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022042891A JP2022042891A (en) | 2022-03-15 |
| JP7595336B2 true JP7595336B2 (en) | 2024-12-06 |
Family
ID=80641560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020148557A Active JP7595336B2 (en) | 2020-09-03 | 2020-09-03 | Antibacterial Water Composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7595336B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023028568A (en) * | 2021-08-19 | 2023-03-03 | フマキラー株式会社 | Agent for disinfection and virus inactivation |
| JP7788056B2 (en) * | 2022-03-10 | 2025-12-18 | 積水化学工業株式会社 | Virus infection inhibitor, virus infection inhibitor product, virus infection inhibitor paint, and resin composition |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017094905A1 (en) | 2015-12-02 | 2017-06-08 | 金印株式会社 | Hair restoration/growth stimulating agent |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4644589B2 (en) * | 2005-07-20 | 2011-03-02 | 株式会社エー・アイ・システムプロダクト | Negative ion water production method and negative ion water |
| JP7176712B2 (en) * | 2017-07-19 | 2022-11-22 | 株式会社サニープレイス | Hair cosmetic composition |
-
2020
- 2020-09-03 JP JP2020148557A patent/JP7595336B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017094905A1 (en) | 2015-12-02 | 2017-06-08 | 金印株式会社 | Hair restoration/growth stimulating agent |
Non-Patent Citations (2)
| Title |
|---|
| Ｓ－１００および弊社原料によるウイルス不活化と殺菌効力試験のご報告、株式会社エー・アイ・システムプロダクト、［令和４年７月２７日検索］、［ｏｎｌｉｎｅ］、２０２０年８月６日、インターネット、＜ＵＲＬ：ｈｔｔｐｓ：／／ｗｗｗ．ａｉｓｐ．ｃｏ．ｊｐ／ｎｅｗｓ／ｄｅｔａｉｌｓ／ｄｅｔａｉｌ３９．ｈｔｍｌ＞ |
| 代表者 関根茂、編集者 田村博明他５名、新 化粧品ハンドブック、日光ケミカルズ株式会社他４社、２００６年１０月３０日発行、ｐｐ．３９２－４１１ |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022042891A (en) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6165953B1 (en) | Virus inactivating agent and sanitary material for vesivirus and / or norovirus | |
| US8940792B2 (en) | Antimicrobial composition and methods for using same | |
| JP7595336B2 (en) | Antibacterial Water Composition | |
| CN111700822A (en) | Skin disinfectant and preparation method thereof | |
| KR20090114411A (en) | Wide range antiviral pharmaceutical composition with excellent storage stability | |
| JP7058490B2 (en) | Antibacterial composition that suppresses viruses, bacteria and fungi | |
| JP6595185B2 (en) | Alcohol-based disinfectant | |
| JP2016113373A (en) | Water-soluble composition having antibacterial and antiviral properties | |
| JP2018199635A (en) | Norovirus inactivator and sanitary material | |
| CN115669662B (en) | Low-irritation-stability unitary peroxyacetic acid disinfectant and preparation method thereof | |
| JP2017105723A (en) | Composition having calicivirus inactivation effect | |
| CN114848803B (en) | Bio-based disinfectants and their applications | |
| JP2022125090A (en) | virus inactivating composition | |
| CN101238816A (en) | Single-component activated glutaraldehyde disinfectant and preparation method thereof | |
| JP7442833B2 (en) | Antibacterial method | |
| CN104434994A (en) | Mucocutaneous disinfectant | |
| CN113475530B (en) | Stable disinfectant and preparation method thereof | |
| JP2021175709A (en) | Lotion composition | |
| CN114129552B (en) | Compound disinfectant and production method and application thereof | |
| JP2016117693A (en) | Water-soluble composition having antibacterial and antivirus property | |
| JP7723969B2 (en) | Virus inactivation composition | |
| KR20250141609A (en) | Composition for sterilizing Avian influenza virus, Foot-and-mouth disease virus, African swine fever virus and Lumpy skin disease virus | |
| JP7376903B2 (en) | Virus inactivators and sanitary materials | |
| US20240260569A1 (en) | Disinfectant liquid, preparation method thereof and film layer | |
| JP2025144352A (en) | virus inactivating agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220916 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230201 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230201 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230209 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230302 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20230331 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20230421 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240712 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241119 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7595336 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |